Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Current Taxes (2018 - 2022)

Regenxbio has reported Current Taxes over the past 5 years, most recently at $12.7 million for Q1 2022.

  • Quarterly results put Current Taxes at $12.7 million for Q1 2022, up 216.4% from a year ago — trailing twelve months through Mar 2022 was $12.7 million (up 216.4% YoY), and the annual figure for FY2021 was $11.3 million, up 261.24%.
  • Current Taxes for Q1 2022 was $12.7 million at Regenxbio, up from $11.3 million in the prior quarter.
  • Over the last five years, Current Taxes for RGNX hit a ceiling of $12.7 million in Q1 2022 and a floor of $508000.0 in Q3 2019.
  • Median Current Taxes over the past 5 years was $1.8 million (2018), compared with a mean of $3.8 million.
  • Biggest five-year swings in Current Taxes: crashed 76.88% in 2019 and later surged 261.24% in 2021.
  • Regenxbio's Current Taxes stood at $726000.0 in 2018, then plummeted by 30.03% to $508000.0 in 2019, then surged by 517.13% to $3.1 million in 2020, then surged by 261.24% to $11.3 million in 2021, then increased by 11.89% to $12.7 million in 2022.
  • The last three reported values for Current Taxes were $12.7 million (Q1 2022), $11.3 million (Q4 2021), and $4.0 million (Q1 2021) per Business Quant data.